REOLYSIN®

also known as Pelareorep · Reovirus Type 3 Dearing · Previously REOLYSIN · Reovirus Serotype 3 - Dearing Strain

Developed for: plasma cell myeloma · breast cancer · pancreatic adenocarcinoma · colorectal cancer · pancreatic ductal adenocarcinoma · anal squamous cell carcinoma · breast carcinoma · Ewing sarcoma/peripheral primitive neuroectodermal tumor
+20 more
· fallopian tube carcinoma · female breast carcinoma · fibrosarcoma · head and neck squamous cell carcinoma · infiltrating bladder urothelial carcinoma · leiomyosarcoma · malignant glioma · melanoma · metastatic melanoma · non-small cell lung carcinoma · osteosarcoma · ovarian carcinoma · pancreatic acinar cell carcinoma · primary peritoneal carcinoma · skin cancer · squamous cell lung carcinoma · synovial sarcoma · triple-negative breast carcinoma · undifferentiated pleomorphic sarcoma · prostate cancer
Investigated by: Oncolytics Biotech · National Cancer Institute (NCI) · University of Texas · University of Leeds · AIO-Studien-gGmbH · Adlai Nortye Biopharma Co., Ltd.
+19 more
· Bristol-Myers Squibb · Canadian Cancer Trials Group · Celgene Corporation · City of Hope Medical Center · Crolll Gmbh · Emory University · Incyte Corporation · Montefiore Medical Center · Mridula George, MD · Myeloma UK · NRG Oncology · National Institutes of Health (NIH) · Northwestern University · Phylogeny · PrECOG, LLC. · SOLTI Breast Cancer Research Group · University of Southern California · University of Utah · Yorkshire Cancer Research

Trials 25

today NCT07446322 · Ph 2 NCT05514990 · Ph 1/2 NCT07280377 · Ph 1/2 NCT05519059 · Ph 1 NCT04445844 · Ph 2 NCT04215146 · Ph 2 NCT04102618 · Ph 0 NCT03723915 · Ph 2 NCT03605719 · Ph 1 NCT03282188 · Ph 1/2 NCT03015922 · Ph 1 NCT02723838 · Ph 1 NCT02620423 · Ph 1 NCT02101944 · Ph 1 NCT01656538 · Ph 2 NCT01274624 · Ph 1 NCT01280058 · Ph 2 NCT01199263 · Ph 2 NCT00998192 · Ph 2 NCT00998322 · Ph 2 NCT00984464 · Ph 2 NCT00861627 · Ph 2 NCT00753038 · Ph 2 NCT00503295 · Ph 2 NCT00528684 · Ph 1

20062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 01 trial
Phase 0	NCT04102618	Mar 2019 → Apr 2022	breast cancer	Oncolytics Biotech	Terminated	No outcome recorded Stop: Enrollment
Phase 18 trials
Phase 1	NCT05519059	Oct 2021 → Sep 2022	breast cancer	Adlai Nortye Biopharma Co., Ltd.	Completed	No outcome recorded
Phase 1	NCT03605719	Oct 2018 → Oct 2022	plasma cell myeloma	Emory University	Completed	No outcome recorded
Phase 1	NCT03015922	Jun 2017 → Sep 2021	plasma cell myeloma	University of Leeds	Unknown	No outcome recorded
Phase 1	NCT02723838	Feb → Sep 2017	infiltrating bladder urothelial carcinoma	Oncolytics Biotech	Withdrawn	No outcome recorded
Phase 1	NCT02620423	Dec 2015 → Mar 2018	pancreatic adenocarcinoma	Oncolytics Biotech	Completed	No outcome recorded
Phase 1	NCT02101944	Dec 2014 → May 2021	anemia, plasma cell myeloma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1	NCT01274624	Dec 2010 → Feb 2018	colorectal cancer	Oncolytics Biotech	Completed	No outcome recorded
Phase 1	NCT00528684	Jul 2006 → Apr 2010	malignant glioma	Oncolytics Biotech	Completed	No outcome recorded
Phase 1/23 trials
Phase 1/2	NCT05514990	Oct 2022 → Dec 2026 expected	plasma cell myeloma	University of Southern California	Active not recruiting	No outcome recorded
Phase 1/2	NCT07280377	Oct 2021 → Jul 2027 expected	anal squamous cell carcinoma, pancreatic ductal adenocarcinoma	Oncolytics Biotech	Active not recruiting	No outcome recorded
Phase 1/2	NCT03282188	Oct 2017 → Jul 2018	melanoma, skin cancer	University of Leeds	Withdrawn	No outcome recorded
Phase 213 trials · 3 met primary · 1 missed
Phase 2	NCT07446322	Apr 2026 → Aug 2027 expected	colorectal cancer	Oncolytics Biotech	Recruiting	No outcome recorded
Phase 2	NCT04445844	Jul 2020 → Jun 2025 overdue	female breast carcinoma, triple-negative breast carcinoma	Mridula George, MD	Active not recruiting	No outcome recorded
Phase 2	NCT04215146	Jun 2020 → Aug 2022 overdue	breast carcinoma	Oncolytics Biotech	Active not recruiting	No outcome recorded
Phase 2	NCT03723915	Nov 2018 → Dec 2019	pancreatic adenocarcinoma	Northwestern University	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT01656538	Feb 2013 → Nov 2016	breast cancer	Canadian Cancer Trials Group	Completed	No outcome recorded
Phase 2	NCT01199263	Dec 2010 → Jun 2015	fallopian tube carcinoma, ovarian carcinoma, primary peritoneal carcinoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT01280058	Dec 2010 → Jan 2016	pancreatic acinar cell carcinoma, pancreatic ductal adenocarcinoma	National Cancer Institute (NCI)	Completed	Missed primary
Phase 2	NCT00998192	Oct 2009 → Sep 2013	squamous cell lung carcinoma	Oncolytics Biotech	Completed	Met primary
Phase 2	NCT00998322	Oct 2009 → Dec 2013	pancreatic adenocarcinoma	Oncolytics Biotech	Completed	Met primary
Phase 2	NCT00984464	Sep 2009 → Feb 2014	metastatic melanoma	Oncolytics Biotech	Completed	No outcome recorded
Phase 2	NCT00861627	Mar 2009 → Sep 2015	non-small cell lung carcinoma	Oncolytics Biotech	Completed	No outcome recorded
Phase 2	NCT00753038	Aug 2008 → Jul 2011	head and neck squamous cell carcinoma	Oncolytics Biotech	Completed	No outcome recorded
Phase 2	NCT00503295	Jun 2007 → Feb 2011	Ewing sarcoma/peripheral primitive neuroectodermal tumor, fibrosarcoma, leiomyosarcoma, osteosarcoma +2	Oncolytics Biotech	Completed	Met primary

Comparator or background therapy4 trials
Phase 2	NCT01619813 Comparator	Dec 2012 → Apr 2016	prostate cancer	Canadian Cancer Trials Group	Completed	No outcome recorded
Phase 2	NCT01708993 Comparator	Dec 2012 → Jan 2016	non-small cell lung carcinoma	Canadian Cancer Trials Group	Completed	No outcome recorded
Phase 2	NCT01622543 Comparator	Oct 2012 → Jan 2017	colorectal cancer	Canadian Cancer Trials Group	Completed	No outcome recorded
Phase 3	NCT01166542 Comparator	Jun 2010 → Apr 2012	head and neck squamous cell carcinoma	Oncolytics Biotech	Completed	No outcome recorded

News releases announcing trial results or a regulatory action · 211

Date	Issuer	Release
2026-09-29	Oncolytics Biotech	Results Oncolytics Biotech® Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to Immunotherapy oncolyticsbiotech.com ↗
2026-09-10	Oncolytics Biotech	Results Oncolytics Biotech® Announces Positive Preclinical Results Combining Pelareorep with a Pan-RAS Inhibitor in Colorectal Cancer oncolyticsbiotech.com ↗ Oncolytics Biotech ® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced positive preclinical results evaluating pelareorep in combination with a pan-RAS inhibitor in a RAS-driven colorectal cancer model.
2026-07-20	Oncolytics Biotech	Regulatory Oncolytics Biotech® Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal Cancer oncolyticsbiotech.com ↗
2026-06-01	Oncolytics Biotech	Results Oncolytics Biotech® Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches oncolyticsbiotech.com ↗ Oncolytics Biotech ® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company developing pelareorep, today announced initial data from a preclinical study evaluating pelareorep in combination with RAS inhibitor modalities in a solid tumor model, which demonstrate evidence of greater anti-tumor activity in combination than with the individual approaches alone.
2026-05-22	Oncolytics Biotech	Results Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep’s Potential Across Gastrointestinal Tumors oncolyticsbiotech.com ↗ The combination of pelareorep, letrozole, and atezolizumab resulted in 60% of patients experiencing 30% or greater increases in their CelTIL score.
2026-05-04	Oncolytics Biotech	Results Oncolytics Biotech® Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer oncolyticsbiotech.com ↗ Pelareorep-based combination therapy demonstrated a 19.5-month median duration of response in second-line (“2L”) KRAS-mutant MSS mCRC patients in the REO 022 study, compared to historical benchmarks of approximately 4–6 months in this setting.
2026-03-19	Oncolytics Biotech	Results Oncolytics Biotech® to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026 oncolyticsbiotech.com ↗ The combination of pelareorep, letrozole, and atezolizumab resulted in 60% of patients experiencing 30% or greater increases in their CelTIL score.
2026-02-04	Oncolytics Biotech	Regulatory Oncolytics Biotech® Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer oncolyticsbiotech.com ↗ As part of the Company’s increased focus on gastrointestinal cancer and analysis of the existing colorectal data set in the fall, the Company applied for and has now received Fast Track Designation.
2026-01-12	Oncolytics Biotech	Results Oncolytics Biotech® Announces Updated Clinical Data from GOBLET Cohort 4 Demonstrating Activity of Pelareorep Plus Atezolizumab in Third-Line Anal Cancer oncolyticsbiotech.com ↗ As of the current data cut, four of 14 evaluable third-line patients receiving pelareorep and atezolizumab achieved objective responses, resulting in an objective response rate (“ORR”) of approximately 29%.
2025-12-16	Oncolytics Biotech	Results Oncolytics Biotech® Announces Promising Efficacy and Translational Data Supporting Pelareorep in KRAS-Mutant Metastatic Colorectal Cancer oncolyticsbiotech.com ↗ In that same study, patients receiving the pelareorep, bevacizumab, and FOLFIRI treatment regimen more than doubled progression-free survival and overall survival compared to those receiving bevacizumab and FOLFIRI ( click here for the PR ).
2025-11-19	Oncolytics Biotech	Regulatory Oncolytics Biotech® Aligns with FDA on Pivotal Study Design for Pelareorep in First-Line Pancreatic Cancer oncolyticsbiotech.com ↗ The FDA’s feedback confirms that our design is appropriate to support registration if successful.
2025-10-28	Oncolytics Biotech	Results Oncolytics Biotech® Reports Updated Anal Cancer Data Showing Objective Response Rate More Than Double the Current Standard of Care oncolyticsbiotech.com ↗ The combination of pelareorep and atezolizumab achieved an objective response rate (ORR) of 30% (six among 20 evaluable patients).
2025-09-08	Oncolytics Biotech	Results Oncolytics Biotech® Highlights Strong Efficacy and Translational Data in Metastatic Colorectal Cancer; Will Advance Regulatory Pathway Discussions oncolyticsbiotech.com ↗ In the GOBLET study’s 3L mCRC Cohort 3, pelareorep combined with atezolizumab and TAS-102 met its predefined efficacy endpoint.
2025-09-02	Oncolytics Biotech	Results Oncolytics Biotech® Provides Updated Clinical Safety Data for Pelareorep, Including Across Multiple Gastrointestinal Tumors oncolyticsbiotech.com ↗ An updated analysis involving patients who received at least one intravenous dose of pelareorep demonstrates the existing favorable safety profile of pelareorep in combination with numerous treatment regimens across multiple tumor types.
2025-07-23	Oncolytics Biotech	Results Key Opinion Leader Event Highlights Pelareorep’s Compelling Pancreatic and Gastrointestinal Data And Future Potential oncolyticsbiotech.com ↗ The meaningful survival benefit demonstrated by pelareorep-based treatment combinations in first-line (1L) metastatic pancreatic ductal adenocarcinoma (mPDAC) patients across randomized and single-arm clinical studies necessitates evaluating pelareorep in a registration-enabling study in 1L mPDAC.
2025-07-16	Oncolytics Biotech	Results Oncolytics Biotech® Presents Aggregated Translational Data Providing Evidence of Pelareorep’s Effectiveness Across Multiple Tumor Types oncolyticsbiotech.com ↗ Cross-study data show pelareorep increases PD-L1 expression and boosts cytotoxic T-cell activity, priming resistant tumors for checkpoint inhibitors
2025-07-08	Oncolytics Biotech	Results Oncolytics Biotech® Highlights Transformative Pelareorep Survival Data in Multiple Tumors and Commitment to Registration-Enabling Studies oncolyticsbiotech.com ↗ In addition, a best-in-class 62% objective response rate (ORR) was observed
2025-05-23	Oncolytics Biotech	Results Oncolytics Biotech® to Present New Clinical Trial Data at ASCO Showing Pelareorep’s Unique Immune Activation Capabilities oncolyticsbiotech.com ↗ The presentation highlights pelareorep’s mechanism of action in pancreatic ductal adenocarcinoma (PDAC), offering new insights into how this immunotherapy stimulates multiple arms of the immune system and primes tumors for treatment.
2025-02-19	Oncolytics Biotech	Regulatory Oncolytics Biotech® Advances Key Pancreatic and Anal Cancer Trials, Strengthening Pipeline in 2025 oncolyticsbiotech.com ↗ With positive feedback from regulators in place, we’re advancing our pancreatic cancer study toward full enrollment, and our ASCO GI presentations highlighted pelareorep’s strong safety and efficacy results in two hard-to-treat cancers.
2025-02-18	Oncolytics Biotech	Regulatory Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer oncolyticsbiotech.com ↗ With positive feedback from regulators in place, we’re advancing our pancreatic cancer study toward full enrollment, and our ASCO GI presentations highlighted pelareorep’s strong safety and efficacy results in two hard-to-treat cancers.
2025-01-22	Oncolytics Biotech	Results Oncolytics Biotech® to Present Compelling New Efficacy and Safety Data in Anal and Pancreatic Cancers at 2025 ASCO GI Symposium oncolyticsbiotech.com ↗ In relapsed anal cancer, the efficacy signal that was initially reported continues to outperform historical control trials with the inclusion of additional patients.
2025-01-15	Oncolytics Biotech	Regulatory Regulatory Approval Clears Path for Oncolytics Biotech® to Advance Promising Pancreatic Cancer Treatment, Following a Review of Safety Data oncolyticsbiotech.com ↗ Following a positive safety review by the independent Data Safety Monitoring Board (DSMB), which recommended continuation, the PEI’s approval allows Cohort 5 to progress to full enrollment.
2024-12-03	Oncolytics Biotech	Results Oncolytics Biotech® Reports Completion of Initial Safety Phase Enrollment for GOBLET Trial’s New Pancreatic Cancer Cohort oncolyticsbiotech.com ↗ Early safety and tolerability results from six randomized patients support continued enrollment of pelareorep combined with modified FOLFIRINOX, with or without atezolizumab
2024-09-19	Oncolytics Biotech	Results Oncolytics Biotech® Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study oncolyticsbiotech.com ↗
2024-05-24	Oncolytics Biotech	Results Oncolytics Biotech® ASCO Abstracts Highlight Pelareorep’s Potential in Pancreatic Cancer and Immunotherapeutic Mechanism of Action oncolyticsbiotech.com ↗ Pelareorep treatment increased TIL expansion in the blood in all pancreatic, breast, and colorectal cancer patients evaluated after one cycle of treatment.
2024-05-09	Oncolytics Biotech	Regulatory Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer oncolyticsbiotech.com ↗ Oncolytics is pleased to announce receipt of regulatory clearance to initiate the mFOLFIRINOX cohort in patients with newly diagnosed metastatic PDAC.
2024-03-05	Oncolytics Biotech	Regulatory Oncolytics Biotech® Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN oncolyticsbiotech.com ↗
2023-12-07	Oncolytics Biotech	Results Oncolytics Biotech® and SOLTI Present Positive Translational Data at SABCS oncolyticsbiotech.com ↗ Translational data presented from the AWARE-1 study at SABCS showed that pelareorep induced the expansion of tumor-infiltrating lymphocytes, or TILs, in matched tumor biopsy and peripheral blood samples of newly diagnosed breast cancer patients.
2023-11-09	Oncolytics Biotech	Results Oncolytics Announces the Anal Cancer Cohort of the GOBLET Phase 1/2 Study of Pelareorep and Atezolizumab Has Met the Success Criteria for Efficacy oncolyticsbiotech.com ↗ These results met the pre-specified success criteria for the cohort and exceeded the results from historical controls in similar patient populations 1-7
2023-11-03	Oncolytics Biotech	Results Oncolytics Biotech® and SOLTI Present Further Positive Pelareorep Translational Data at SITC oncolyticsbiotech.com ↗
2023-10-23	Oncolytics Biotech	Results Oncolytics Presents Positive Updated Pancreatic Cancer Data from GOBLET Phase 1/2 Study at ESMO oncolyticsbiotech.com ↗ These data build upon results from previous studies showing the clinical benefit of pelareorep combination therapy in PDAC and support the decision to move to a licensure-enabling study in pancreatic cancer,
2023-10-23	Oncolytics Biotech	Results Oncolytics Achieves Success Criteria for Efficacy in the Third-Line Colorectal Cancer Cohort of the GOBLET Study oncolyticsbiotech.com ↗ The results presented at ESMO met the criteria to advance the study to the next stage, with 4 of 14 enrolled patients demonstrating stable disease at week 16.
2023-10-16	Oncolytics Biotech	Results Oncolytics Biotech® To Present Two Posters on the Pelareorep-Based GOBLET Study at ESMO 2023 oncolyticsbiotech.com ↗ The authors concluded from these data that the combination of pelareorep, atezo and chemotherapy was well-tolerated and that the ORR exceeded the pre-specified success criterion.
2023-06-05	Oncolytics Biotech	Results Oncolytics Biotech® Announces Updated Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial that Show Pelareorep Driving Robust Increases in Progression-Free Survival and Confirmed Overall Response Rate oncolyticsbiotech.com ↗
2023-05-25	Oncolytics Biotech	Results Oncolytics Biotech® Announces Positive Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial Demonstrating Pelareorep Drives ≥50% Improvements in ORR and mPFS in an ASCO Annual Meeting Abstract oncolyticsbiotech.com ↗ This cohort also reported median progression-free survival (mPFS) of 9.6 months vs. 6.4 months as of the cut-off date.
2022-12-08	Oncolytics Biotech	Results Oncolytics Biotech’s ® Chinese Development Partner Adlai Nortye Presents Interim Clinical Data Further Demonstrating the Anti-Cancer Activity of Pelareorep-Paclitaxel Combination Therapy in HR+/HER2- Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium oncolyticsbiotech.com ↗ Disease control, partial response (PR) or stable disease (SD), was achieved in thirteen of fourteen evaluable patients (93%), with twelve (86%) showing tumor shrinkage from baseline.
2022-12-01	Oncolytics Biotech	Regulatory Oncolytics Biotech ® Receives FDA Fast Track Designation for the Treatment of Advanced/Metastatic Pancreatic Cancer oncolyticsbiotech.com ↗ today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to pelareorep in combination with Roche’s anti-PD-L1 checkpoint inhibitor atezolizumab, and the chemotherapeutic agents gemcitabine and nab-paclitaxel, for the treatment of advanced/metastatic pancreatic ductal adenocarcinoma (PDAC).
2022-11-21	Oncolytics Biotech	Results Oncolytics Biotech ® Announces Presentations at the Upcoming San Antonio Breast Cancer Symposium oncolyticsbiotech.com ↗ Results published in the SABCS abstract indicate that pelareorep in combination with paclitaxel was safe, well tolerated, and showed anti-tumor activity in Adlai Nortye’s single-arm bridging clinical trial in Chinese patients with advanced or metastatic HR+/HER2- breast cancer.
2022-11-10	Oncolytics Biotech	Results Oncolytics Biotech ® Presents Updated Clinical Data at SITC Annual Meeting Showing a 69% Objective Response Rate and Confirmed Complete Response in GOBLET Study’s Pancreatic Cancer Cohort oncolyticsbiotech.com ↗ Objective response rate (ORR) and clinical benefit rate (CBR) in GOBLET’s PDAC cohort (n=13) were 69% and 85%, respectively , as of the SITC poster’s data cutoff date (October 12, 2022).
2022-11-07	Oncolytics Biotech	Results Oncolytics Biotech ® Reports Third Quarter 2022 Financial Results and Recent Operational Highlights oncolyticsbiotech.com ↗ Clinical interim data reported earlier today from GOBLET trial’s pancreatic cancer cohort show an objective response rate (ORR) nearly triple the average ORR seen in relevant historical control trials
2022-11-07	Oncolytics Biotech	Results Oncolytics Biotech ® Reports Interim Results from Phase 1/2 GOBLET Study Showing a 70% Objective Response Rate in Pancreatic Cancer at the SITC Annual Meeting oncolyticsbiotech.com ↗
2022-06-28	Oncolytics Biotech	Results Oncolytics Biotech® Achieves Success Criteria for Efficacy in the Pancreatic Cancer Cohort of GOBLET oncolyticsbiotech.com ↗
2022-05-04	Oncolytics Biotech	Results Oncolytics Biotech® and SOLTI Present New Clinical Biomarker Data Demonstrating Pelareorep’s Potential to Improve the Prognosis of Breast Cancer Patients at the ESMO Breast Cancer Meeting oncolyticsbiotech.com ↗ Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC) and SOLTI-Innovative Cancer Research today announced new clinical biomarker data demonstrating pelareorep’s immunotherapeutic effects, synergy with checkpoint inhibition, and potential to improve the outlook for patients with HR+/HER2- breast cancer.
2022-05-02	Oncolytics Biotech	Results Oncolytics Biotech® and SOLTI Announce Upcoming Poster Presentation at the European Society for Medical Oncology Breast Cancer Meeting oncolyticsbiotech.com ↗ Results of this exploratory study described in the abstract show pelareorep’s potential to induce an inflamed tumor phenotype and its synergy with atezolizumab.
2022-04-14	Oncolytics Biotech	Results Oncolytics Biotech® Announces Publication of Preclinical Data Demonstrating the Synergistic Anti-Cancer Activity of Pelareorep Combined with CAR T Cell Therapy in Solid Tumors in Science Translational Medicine oncolyticsbiotech.com ↗ today announced the publication of preclinical data demonstrating the synergistic anti-cancer activity of pelareorep combined with chimeric antigen receptor (CAR) T cell therapy in solid tumors.
2022-04-08	Oncolytics Biotech	Results Oncolytics Biotech® Presents New Data Demonstrating Durable Clinical Benefit in Relapsed/Refractory Multiple Myeloma Patients at the AACR Annual Meeting oncolyticsbiotech.com ↗ Pelareorep’s immunotherapeutic effects produced progression-free survival of >3 years in a subset of multiple myeloma patients who had failed prior therapy
2022-04-08	Oncolytics Biotech	Results Oncolytics Biotech® Announces Positive Long-Term Survival Data from Phase 1b Glioblastoma Multiforme Trial at the AACR Annual Meeting oncolyticsbiotech.com ↗ The results, which are the subject of a presentation at the American Association for Cancer Research (AACR) Annual Meeting, show a substantial and durable efficacy signal in newly diagnosed GBM patients and demonstrate the safety and tolerability of the studied treatment combination in this indication.
2022-03-31	Oncolytics Biotech	Results Oncolytics Biotech® Provides Positive Safety Update on the Third-Line Metastatic Colorectal Cancer Cohort of its Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial oncolyticsbiotech.com ↗ The DSMB noted no safety concerns in these patients and has recommended that the study proceed to full enrollment pending clearance by the Paul Ehrlich Institute (PEI; Germany’s medical regulatory body).
2022-03-24	Oncolytics Biotech	Results Oncolytics Biotech® Partner Adlai Nortye Advances Chinese Bridging Trial of Pelareorep-Paclitaxel Combination Treatment in Breast Cancer to Final Dosing Cohort oncolyticsbiotech.com ↗ The trial’s first two cohorts have completed their dose escalation evaluation periods and indicated pelareorep in combination with paclitaxel was well-tolerated with no new safety signals observed to date.
2022-03-17	Oncolytics Biotech	Results Oncolytics Biotech® Announces Publication of Preclinical and Patient Data Demonstrating Pelareorep’s Stimulation of Natural Killer Cell Anti-Cancer Activity oncolyticsbiotech.com ↗ Results showed pelareorep treatment led to the activation of NK cells, which are known to directly kill cancer cells while stimulating adaptive anti-tumor immunity.
2022-03-09	Oncolytics Biotech	Results Oncolytics Biotech® Announces Phase 1b Data Demonstrating Clinical Proof-of-Concept for Pelareorep-Proteasome Inhibitor Combination in Multiple Myeloma in an Abstract at the AACR Annual Meeting oncolyticsbiotech.com ↗ Results from the trial showed that the combination was well-tolerated and led to prolonged progression-free survival (PFS) of over three years in a subset of patients.
2022-02-02	Oncolytics Biotech	Results Oncolytics Biotech® Provides Positive Safety Update on the Pancreatic Cancer Cohort of its Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial oncolyticsbiotech.com ↗ The DSMB noted no safety concerns in these patients and recommended the study proceed as planned.
2021-12-15	Oncolytics Biotech	Results Oncolytics Biotech® Announces the Presentation of Preclinical Data Demonstrating the Synergistic Anti-Leukemic Effects of Pelareorep Combined with Azacitidine at the 2021 American Society of Hematology Annual Meeting oncolyticsbiotech.com ↗ Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC) announced preclinical data demonstrating the synergistic anti-leukemic effects of pelareorep combined with the chemotherapeutic agent azacitidine.
2021-12-10	Oncolytics Biotech	Results Oncolytics Biotech® Presents Positive Interim Safety Update from Phase 2 Triple-Negative Breast Cancer Trial at the 2021 San Antonio Breast Cancer Symposium oncolyticsbiotech.com ↗ Safety data from the trial show that the combination has been well-tolerated, as no safety concerns have been noted in any of the five patients enrolled in the trial at the time of reporting.
2021-09-20	Oncolytics Biotech	Results Oncolytics Biotech® Announces Preclinical Data Demonstrating the Synergistic Immunotherapeutic Effects of Pelareorep Combined with Radiotherapy oncolyticsbiotech.com ↗ Results showed that in primary tumors, pelareorep monotherapy led to a numerical increase in the number of infiltrating anti-cancer CD8+ T cells, which reached statistical significance when combined with radiotherapy (a 15-fold increase compared to control).
2021-05-20	Oncolytics Biotech	Results Oncolytics Biotech® Announces Clinical and Biomarker Data Demonstrating Clinical Proof-of-Concept for Pelareorep-Checkpoint Inhibitor Combination in Pancreatic Cancer oncolyticsbiotech.com ↗ Findings from the trial indicate that pelareorep and pembrolizumab synergize and show anti-cancer activity in these difficult-to-treat patients, which is mediated through the complementary immunotherapeutic effects of the two agents.
2021-04-12	Oncolytics Biotech	Results Oncolytics Biotech® Presents Preclinical Data on Pelareorep-based Combination Therapies at the AACR Annual Meeting oncolyticsbiotech.com ↗
2021-04-12	Oncolytics Biotech	Results Oncolytics Biotech® and SOLTI Achieve Primary Endpoint in AWARE-1 Study oncolyticsbiotech.com ↗ Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), together with SOLTI, recently announced new clinical data from the AWARE-1 window-of-opportunity breast cancer study showing patients receiving pelareorep plus checkpoint blockade therapy met the trial’s primary endpoint.
2021-03-10	Oncolytics Biotech	Results Oncolytics Biotech® Announces Upcoming Presentations at the AACR Annual Meeting oncolyticsbiotech.com ↗ Data show that combining pelareorep with palbociclib augmented pelareorep-induced endoplasmic reticulum (ER) stress signaling and increased innate immune activation and effector function.
2021-02-23	Oncolytics Biotech	Results Oncolytics Biotech® Reports Preclinical Data Demonstrating the Synergistic Anti-cancer Activity of Pelareorep Combined with CAR T Cell Therapy in Solid Tumors oncolyticsbiotech.com ↗ These synergistic immune effects were specific to pelareorep, as intravenous boosting with VSV did not augment CAR/Pela therapy or prevent the growth of recurrent tumors.
2020-12-09	Oncolytics Biotech	Results Oncolytics and SOLTI Report Clinical Synergy of Pelareorep with Checkpoint Inhibitors at the 2020 San Antonio Breast Cancer Symposium oncolyticsbiotech.com ↗ Treatment with pelareorep increased the CelTIL score in tumor biopsies, which has been associated with improved clinical outcomes.
2020-11-19	Oncolytics Biotech	Results Oncolytics Biotech® Announces Positive Clinical Results Against Glioblastoma Multiforme at the 2020 Society of Neuro-Oncology Annual Meeting oncolyticsbiotech.com ↗ The results, which were featured in a podium presentation at the 2020 Society of Neuro-Oncology Annual Meeting, show a compelling signal of efficacy and demonstrate the safety and tolerability of the pelareorep-based combination therapy in newly diagnosed GBM patients.
2020-11-09	Oncolytics Biotech	Results Oncolytics Biotech® Announces Abstract Publication and Upcoming Oral Presentation at the 2020 Society of Neuro-Oncology Annual Meeting oncolyticsbiotech.com ↗ Data from a phase 1b, investigator-sponsored study show that a pelareorep-based combination therapy is safe and well-tolerated in newly diagnosed glioblastoma multiforme patients
2020-11-09	Oncolytics Biotech	Results Oncolytics Biotech® and SOLTI Present Clinical Breast Cancer Data Highlighting Pelareorep-Induced Anti-Tumor T Cell Responses at The Society for Immunotherapy of Cancer Annual Meeting oncolyticsbiotech.com ↗ 70% of cohort-1 patients saw an increase in CelTIL, the study’s primary endpoint and a measure of tumor inflammation that is associated with favorable clinical outcomes
2020-05-29	Oncolytics Biotech	Results Oncolytics Biotech® Presents Clinical Proof-of-Concept Data in Multiple Myeloma at the ASCO Virtual Annual Meeting oncolyticsbiotech.com ↗ Data presented in the ePoster demonstrates that the pelareorep-carfilzomib combination treatment results in selective replication of pelareorep in cancer cells and beneficial induction of an inflamed tumor environment associated with clinical responses.
2020-05-26	Oncolytics Biotech	Results Oncolytics Biotech® Presents Clinical Data Supporting a Predictive Biomarker of Pelareorep Response in Breast Cancer at the ESMO Breast Cancer Virtual Meeting oncolyticsbiotech.com ↗ The data demonstrates a pelareorep-induced adaptive immune response in the tumor microenvironment (TME) and the potential of a predictive biomarker (T cell clonality) to identify patients with breast cancer most likely to respond to pelareorep.
2020-05-14	Oncolytics Biotech	Results Oncolytics Biotech® Announces Publication of Abstracts at the 2020 American Society of Clinical Oncology Virtual Annual Meeting oncolyticsbiotech.com ↗ Pelareorep and pembrolizumab combination therapy was well tolerated with encouraging clinical results in second-line pancreatic cancer
2020-05-04	Oncolytics Biotech	Results Oncolytics Biotech® to Present Clinical Findings of Pelareorep-Induced Immune Response in Breast Tumors at the ESMO Breast Cancer Virtual Meeting oncolyticsbiotech.com ↗ The Abstract reported that pelareorep treated patients experienced productive and tumor cell-specific pelareorep replication, an increase in CD8+ T cells, and an upregulation of the immune-checkpoint marker PD-L1.
2020-04-02	Oncolytics Biotech	Results Oncolytics Biotech® Announces Publication of Pelareorep’s Clinical Benefit Against KRAS Mutated Colorectal Cancer oncolyticsbiotech.com ↗ Among 30 evaluable patients, 6 (20%) had a partial response (PR) and 22 patients (73.3%) had stable disease (SD) as their best response, for a clinical benefit rate (PR +SD) of 93.3%.
2020-03-24	Oncolytics Biotech	Results Oncolytics Biotech® Announces Favourable AWARE-1 Safety Update oncolyticsbiotech.com ↗ The Committee evaluated safety parameters from patients participating in the safety run-in phase of the trial, consisting of select patients from cohorts 2 and 3, along with the fully enrolled cohort 1, and determined there were no safety concerns.
2020-01-27	Oncolytics Biotech	Results Oncolytics Biotech® Announces Statistically Significant Data Identifying CEACAM6 as a Prospective Prognostic Biomarker for Pelareorep in the Treatment of Pancreatic Adenocarcinoma oncolyticsbiotech.com ↗ Data in the presentation associate low levels of the gene CEACAM6 with prolonged progression free survival (PFS) in pelareorep-treated patients with pancreatic cancer.
2020-01-22	Oncolytics Biotech	Results Oncolytics Biotech® Announces Publication of an Abstract for the 2020 Gastrointestinal Cancers Symposium Highlighting CEACAM6 as a Potential Prognostic Biomarker Candidate for Pancreatic Cancer oncolyticsbiotech.com ↗ Data in the abstract associate low levels of the gene CEACAM6 with prolonged progression free survival (PFS) in pelareorep-treated patients with pancreatic cancer, with PFS improving from 5.72 months to 10.32 months (p=0.05).
2020-01-13	Oncolytics Biotech	Results Oncolytics Biotech® Provides Recap of Key Opinion Leader Call Highlighting Pelareorep’s Unique Ability to Activate the Immune System in Late Stage Multiple Myeloma oncolyticsbiotech.com ↗ “I think that carfilzomib promotes pelareorep infection by suppressing the innate antiviral response and our data suggest that it does not get in the way of T-cell activation,” said Dr. Hofmeister.
2019-12-09	Oncolytics Biotech	Results Oncolytics Biotech(R) Announces Positive Multiple Myeloma Data Presented at the 61st Annual Meeting & Exposition of the American Society of Hematology oncolyticsbiotech.com ↗ Oncolytics Biotech ® Inc. (NASDAQ:ONCY)(TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that a poster presentation was given over the weekend highlighting pre-clinical and clinical results of combining pelareorep with the proteasome inhibitor carfilzomib in the treatment of multiple myeloma.
2019-11-08	Oncolytics Biotech	Results Oncolytics Biotech(R) Announces AWARE-1 Data Presented at the 34th Annual Meeting of the Society for Immunotherapy of Cancer oncolyticsbiotech.com ↗ This initial data shows replication of pelareorep occurs exclusively in tumor tissue and there is an increase in CelTIL through the expansion of existing T cells, and most importantly, through the creation of new T cell clones.
2019-11-07	Oncolytics Biotech	Results Oncolytics Biotech(R) Announces Abstract Published for the 61st Annual Meeting & Exposition of the American Society of Hematology oncolyticsbiotech.com ↗ Oncolytics Biotech ® Inc. (NASDAQ:ONCY)(TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the publication of an abstract highlighting the pre-clinical results of combining pelareorep with the proteasome inhibitor carfilzomib in the treatment of multiple myeloma.
2019-11-06	Oncolytics Biotech	Results Oncolytics Biotech(R) Announces Publication of Positive REO 024 Study Results for Pelareorep in Combination with Keytruda(R) in Patients with Advanced Pancreatic Adenocarcinoma oncolyticsbiotech.com ↗ “Pelareorep and pembrolizumab added to chemotherapy was safe and well-tolerated and demonstrated encouraging efficacy results,”
2019-10-31	Oncolytics Biotech	Regulatory Oncolytics Biotech(R) Provides Update on Partner Adlai Nortye’s Clinical Progress oncolyticsbiotech.com ↗ Adlai received National Medical Products Administration approval for phase 3 clinical trials in China
2019-10-15	Oncolytics Biotech	Results Oncolytics Biotech(R) Presents Clinical Data Highlighting the Effectiveness of Intravenous Delivery to and Replication of Pelareorep in Tumors oncolyticsbiotech.com ↗ The data demonstrated that, unlike other oncolytic viruses that require intra-tumoral delivery, intravenous (IV) systemic delivery of pelareorep resulted in 81% of patient tumor samples across multiple types of cancer testing positive for virus replication, with no infection in normal tissue.
2019-07-23	Oncolytics Biotech	Results Oncolytics Biotech(R) Announces Preliminary AWARE-1 Trial Data Demonstrating Viral Replication and Promotion of Inflammation Following Systemic Administration of Pelareorep When Combined with Tecentriq(R) oncolyticsbiotech.com ↗ All three patients demonstrated immunohistochemically positive viral replication in the tumor mass – two of the three patients showed greater than 50% of the tumor cells infected – following intravenous administration, generating inflammation and T cell recruitment at the tumor site.
2019-05-16	Oncolytics Biotech	Results Oncolytics Biotech (R) Publishes Abstract Highlighting Additional Biomarker Analyses at the 2019 American Society of Clinical Oncology Annual Meeting oncolyticsbiotech.com ↗ Gene expression analysis in peripheral blood mononuclear cells (PBMCs) helps to validate the changes in T cell diversity, where responding patients had higher levels of pro-inflammatory cytokines expressed by activated T cells, compared to non-responders.
2019-04-02	Oncolytics Biotech	Results Oncolytics Biotech (R) Presents Positive Clinical Biomarker Data at the American Association for Cancer Research Annual Meeting 2019 oncolyticsbiotech.com ↗ The data presented at AACR now demonstrate that the degree of T cell clonality, examined in patients from REO 024, has the potential to serve as a predictive and prognostic biomarker of pelareorep therapy.
2019-03-28	Oncolytics Biotech	Results Oncolytics Biotech (R) Announces a Publication Highlighting Synergistic Effect of Pelareorep with a Proteasome Inhibitor in Preclinical Models of Multiple Myeloma oncolyticsbiotech.com ↗
2019-03-21	Adlai Nortye Biopharma Co., Ltd.	Regulatory Adlai Nortye Receives NMPA Approval for Pelareorep Phase III Clinical Trials adlainortye.com ↗ it has received a clearance from the National Medical Products Administration (NMPA) of China for initiating the open-label, randomized, multicenter, global phase III clinical trial for pelareorep
2019-02-27	Oncolytics Biotech	Results Oncolytics Biotech(R) Presents Biomarker Data in Second-line Pancreatic Cancer at AACR oncolyticsbiotech.com ↗ Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the publication of an abstract demonstrating a biomarker for predicting clinical response in patients treated with pelareorep.
2019-02-11	Oncolytics Biotech	Regulatory Oncolytics Biotech(R) Announces Spanish Regulatory Approval of AWARE-1 Window of Opportunity Study in Breast Cancer oncolyticsbiotech.com ↗ today announced that the Spanish Agency for Medicine and Health Products has granted final approval for the forthcoming AWARE-1 window of opportunity study in breast cancer.
2018-12-03	Oncolytics Biotech	Results Oncolytics Biotech® Announces Increased PD-L1 Expression When Combining Pelareorep with a Proteasome Inhibitor in Poster Presentation at the 60th American Society of Hematology Annual Meeting & Exposition oncolyticsbiotech.com ↗ The data in this poster clearly demonstrate an increase in viral infection and viral replication, as well as pelareorep-dependent PD-L1 increased expression on the surface of myeloma cells, among patients undergoing treatment with pelareorep in combination with carfilzomib.
2018-11-09	Oncolytics Biotech	Results Oncolytics Biotech® Announces Presentation at the Society for Immunotherapy of Cancer 2018 Annual Meeting Showcasing Upregulation of PD-L1 Expression with Reovirus Infection oncolyticsbiotech.com ↗
2018-11-01	Oncolytics Biotech	Results Oncolytics Biotech® Announces Abstract for ASH Annual Meeting & Exposition Demonstrating Pelareorep Increases PD-L1 Expression When Combined with a Proteasome Inhibitor oncolyticsbiotech.com ↗ In part one of the study, six carfilzomib-sensitive patients showed reovirus infection and replication in the post-treatment bone marrow aspirates.
2018-10-22	Oncolytics Biotech	Results Oncolytics Biotech® Announces Positive Clinical Trial Results for Pelareorep in Patients with KRAS Mutant Metastatic Colorectal Cancer for Presentation at ESMO 2018 oncolyticsbiotech.com ↗ Patients receiving treatment with the recommended phase 2 dose (RPTD) of pelareorep (“Reo”) in combination with FOLFIRI/B (irinotecan, fluorouracil, leucovorin, plus bevacizumab) had progression free survival (PFS) of 65.6 weeks and an overall survival (OS) of 107.5 weeks, which exceeded expectations when compared to historical data.
2018-10-11	Oncolytics Biotech	Results Oncolytics Biotech® Announces Publication of Positive Clinical Results for Pelareorep in Abstract for ESMO 2018 Congress oncolyticsbiotech.com ↗ Thirty-six patients received treatment with FOLFIRI/B and pelareorep, and the results demonstrated that the combination is not only safe and well tolerated, but that progression free survival (PFS) and overall survival (OS) are significantly superior to historical data.
2018-10-02	Oncolytics Biotech	Results Oncolytics Biotech® Announces a Publication Demonstrating That Intravenously Delivered Oncolytic Viruses Effectively Target Tumors Even in the Presence of Neutralizing Antibodies oncolyticsbiotech.com ↗ The research showed that pelareorep, a systemically delivered oncolytic reovirus, can destroy tumor cells via a monocyte-mediated process even after the virions have been exposed to antibodies designed to neutralize the reovirus.
2018-06-04	Oncolytics Biotech	Results Oncolytics Biotech® Announces Poster Presentation Demonstrating the Ability of REOLYSIN® to Promote and Predict Response to Checkpoint Inhibitors at ASCO 2018 Annual Meeting oncolyticsbiotech.com ↗ “These results demonstrate that pelareorep promotes the expression of gene signatures predictive of a response to immunotherapy in breast cancer and hepatocellular carcinoma,” said Matt Coffey, President and CEO of Oncolytics Biotech.
2018-05-16	Oncolytics Biotech	Results Oncolytics Biotech® Announces Publication of REOLYSIN® Abstract for the ASCO 2018 Annual Meeting oncolyticsbiotech.com ↗ The results suggest that all cell lines are susceptible to pelareorep’s induced cytopathic effect.
2018-05-10	Oncolytics Biotech	Regulatory Oncolytics Biotech® Receives Special Protocol Assessment Agreement from FDA for Phase 3 Clinical Trial of Pelareorep In Metastatic Breast Cancer oncolyticsbiotech.com ↗
2018-04-18	Oncolytics Biotech	Results Oncolytics Biotech(R) Demonstrates Positive Data in Two Posters at AACR Annual Meeting 2018 oncolyticsbiotech.com ↗ The study by doctor Wilkinson demonstrates that pelareorep can establish an inflamed tumor phenotype and the presentation by doctor Goel highlights the synergistic combination of pelareorep and an anti-PD1 agent.
2018-04-10	Oncolytics Biotech	Results Oncolytics Biotech(R) Presents Positive REOLYSIN(R) Data in Combination with Keytruda and anti-CD73 at International Oncolytic Virus Conference 2018 oncolyticsbiotech.com ↗ treatment of subcutaneous TRAMP-C2 prostate tumors with a combination of pelareorep and anti-PD-1 (Keytruda ® ) or anti-CD73 antibody significantly enhanced survival of mice compared to pelareorep or antibody therapy alone
2018-03-14	Oncolytics Biotech	Results Oncolytics Biotech(R) Announces Publication of REOLYSIN(R) Abstract for the AACR 2018 Annual Meeting oncolyticsbiotech.com ↗ This most recent data shows that pelareorep, an immuno-oncolytic virus, or IOV, elicits an interferon-ɣ-proinflammatory gene signature in select cancer cells permissive to viral infection, which could activate and expand T-cell and natural killer cell populations at the tumor site,
2018-01-19	Oncolytics Biotech	Results Oncolytics Biotech(R) Announces Poster Presentation at the 2018 Gastrointestinal Cancers Symposium Sponsored by ASCO in Patients with Relapsed Metastatic Adenocarcinoma of the Pancreas oncolyticsbiotech.com ↗ The poster outlines six efficacy evaluable patients, including one that had partial response lasting 17.4 months and two with stable disease of 126 days and 277 days.
2018-01-16	Oncolytics Biotech	Results Oncolytics Biotech® Announces Abstract for Poster Presentation at the 2018 Gastrointestinal Cancers Symposium Sponsored by ASCO in Patients with Relapsed Metastatic Adenocarcinoma of the Pancreas oncolyticsbiotech.com ↗ The abstract also demonstrates manageable safety profiles and antitumor activity in previously treated patients with metastatic or advanced pancreatic adenocarcinoma.
2017-12-05	Oncolytics Biotech	Regulatory Oncolytics Biotech® Receives Favorable Final Advice Letter from the European Medicines Agency for REOLYSIN® in Metastatic Breast Cancer oncolyticsbiotech.com ↗ The Letter refers to the proposed use of pelareorep in combination with paclitaxel, for the treatment of hormone receptor positive, HER2 receptor negative (HR+/HER2-) metastatic breast cancer patients in a pivotal phase 3 registration study and suggests that a single 400-patient study may be acceptable to form the basis of a Marketing Authorization Application (MAA) in Europe.
2017-09-11	Oncolytics Biotech	Results Oncolytics Biotech® Announces the Presentation of REOLYSIN® Clinical Data at ESMO 2017 Congress oncolyticsbiotech.com ↗
2017-05-17	Oncolytics Biotech	Results Oncolytics Biotech® Announces ASCO Abstracts and Preliminary Data for Studies in Pancreatic and Prostate Cancers oncolyticsbiotech.com ↗ Three of five efficacy evaluable patients showed a tumor response (secondary endpoint), with one having a partial response (six-month duration) and two having stable disease (lasting 126 and 221 days).
2017-05-08	Oncolytics Biotech	Regulatory Oncolytics Biotech® Inc. Announces FDA Fast Track Designation for REOLYSIN® in Metastatic Breast Cancer oncolyticsbiotech.com ↗ Oncolytics Biotech ® Inc. (Oncolytics or the Company) (TSX:ONC) (OTCQX:ONCYF) announced today that the United States Food and Drug Administration (FDA) has granted Fast Track designation for REOLYSIN ® , the Company’s proprietary immuno-oncology viral agent, for the treatment of metastatic breast cancer.
2017-04-05	Oncolytics Biotech	Results Oncolytics Biotech® Inc.’s REOLYSIN® More than Doubles Overall Survival in Patients with Mutated p53 Metastatic Breast Cancer oncolyticsbiotech.com ↗ today announced data demonstrating a statistically significant (p=0.03) overall survival (OS) benefit for patients with mutated p53 metastatic breast cancer, when treated with REOLYSIN ® , an immuno-oncology viral agent, in combination with paclitaxel.
2017-03-31	Oncolytics Biotech	Results Oncolytics Biotech® Inc.’s REOLYSIN® Provides Statistically Significant Improvement in Overall Survival in Canadian Cancer Trials Group Sponsored Randomized Phase 2 Study in Metastatic Breast Cancer oncolyticsbiotech.com ↗
2016-12-06	Oncolytics Biotech	Results Oncolytics Biotech® Inc. Collaborators Present Initial Results from REO 019 Study in Multiple Myeloma Combining REOLYSIN®, Bortezomib and Dexamethasone at the ASH Annual Meeting oncolyticsbiotech.com ↗ Preliminary evidence of activity of this combination was documented.
2016-08-10	Oncolytics Biotech	Results Oncolytics Biotech® Inc. Reports Additional Data from Randomized Phase II Study of REOLYSIN® in Non-Small Cell Lung Cancer oncolyticsbiotech.com ↗ The PFS was statistically significantly better for female patients in the test arm (n=20) than for those in the control arm (n=16); median PFS was 5.39 months compared with 3.02 months, respectively (p=0.0201) (Figure A).
2016-06-29	Oncolytics Biotech	Regulatory Oncolytics Biotech® Inc. Announces Phase 2 Study in Female Patients with Colorectal Cancer Metastatic to the Liver oncolyticsbiotech.com ↗ the Investigational New Drug Application containing the protocol titled “Phase 2 study of REOLYSIN ® (pelareorep) in combination with FOLFOX6, bevacizumab and pembrolizumab in female patients with KRAS-mutant colorectal cancer metastatic to the liver” is now active.
2016-05-19	Oncolytics Biotech	Results Oncolytics Biotech® Inc. Reports Preliminary Data from Randomized Phase II Study of REOLYSIN® in Non-Small Cell Lung Cancer oncolyticsbiotech.com ↗ Oncolytics Biotech Inc. (“ Oncolytics ” or the “ Company “) (TSX: ONC) (OTCQX: ONCYF) (FRA: ONY) today announced preliminary data from a randomized, Phase II clinical study of REOLYSIN ® .
2016-05-19	Oncolytics Biotech	Results Oncolytics Biotech® Inc. Reports Preliminary Data from Randomized Phase II Study of REOLYSIN® in Colorectal Cancer oncolyticsbiotech.com ↗ The abstract reported that the overall test arm had an objective response rate of 52.9% (n=51) versus 34.6% (n=52) in the control arm (p=0.06).
2016-05-05	Oncolytics Biotech	Results Oncolytics Biotech® Inc. Announces Presentation of REOLYSIN® Preclinical Research at the 2016 ASGCT Annual Meeting oncolyticsbiotech.com ↗ The data demonstrates that combination of reovirus plus SAHA therapy has significant activity in the treatment of SCCHN, even in an immunocompetent model and that immune system rebound likely plays a significant role in the long-term anti-tumor response.
2016-04-18	Oncolytics Biotech	Results Oncolytics Biotech® Inc. Collaborators Present REOLYSIN® Preclinical Research at the 2016 AACR Annual Meeting oncolyticsbiotech.com ↗ Using the VK*MYC bortezomib resistant transplantable multiple myeloma mouse model, the authors demonstrated that mice harboring bortezomib insensitive multiple myeloma tumors significantly responded to reovirus treatment.
2016-04-14	Oncolytics Biotech	Results Oncolytics Biotech® Inc. Reports Updated Data from Randomized Phase 2 Study of REOLYSIN® in Pancreatic Cancer oncolyticsbiotech.com ↗ The analysis showed a statistically significantly higher percentage of patients surviving two years in the test arm versus the control arm (p = 0.001), the crossover arm versus the control arm (p = 0.03) and the test plus crossover arms versus the control arm (p = 0.0004).
2016-03-21	Oncolytics Biotech	Results Oncolytics Biotech® Inc. Reports Data from Randomized Phase 2 Study of REOLYSIN® in Ovarian Cancer oncolyticsbiotech.com ↗ The Company performed an intent-to-treat analysis of tumour response, as assessed by CA-125 antigen levels, which showed statistically significantly higher full response rates and stable disease or better rates in the test arm versus the control arm.
2015-12-08	Oncolytics Biotech	Results Oncolytics Biotech® Inc. Collaborators Present Multiple Myeloma Data at 57th American Society of Hematology Annual Meeting oncolyticsbiotech.com ↗
2015-10-20	Oncolytics Biotech	Regulatory Oncolytics Biotech® Inc. Announces Phase 1b Study in Advanced Pancreatic Cancer oncolyticsbiotech.com ↗
2015-09-25	Oncolytics Biotech	Results Oncolytics Biotech® Inc. Collaborators Present Data from Clinical Study in Multiple Myeloma oncolyticsbiotech.com ↗ 100% of patients (8 of 8) experienced an objective response as measured by changes in blood monoclonal protein.
2015-08-27	Oncolytics Biotech	Results Oncolytics Biotech® Inc. Collaborators to Present Survival Data from REO 016 Study in Non-Small Cell Lung Cancer oncolyticsbiotech.com ↗ “Our research collaborators are noting the two-year survival data from this study, which is high for later-stage patients with recurrent or metastatic disease,” said Dr. Matt Coffey, COO of Oncolytics.
2015-07-06	Oncolytics Biotech	Results Oncolytics Biotech® Inc. Collaborators Present Final Data from REO 017 Clinical Study in Pancreatic Cancer oncolyticsbiotech.com ↗ The poster, titled “Oncolytic Virus Therapy in Pancreatic Cancer: Clinical Efficacy and Pharmacodynamic Analysis of REOLYSIN ® in Combination with Gemcitabine in Patients with Advanced Pancreatic Adenocarcinoma,” covers final results from the Company’s REO 017 Phase 2 study.
2015-06-15	Oncolytics Biotech	Results Oncolytics Biotech® Inc. Collaborators Present REOLYSIN® Preclinical Data at the 9th International Conference on Oncolytic Virus Therapeutics oncolyticsbiotech.com ↗ They concluded that the combination of reovirus and ABT-263 could increase direct and immune-mediated killing of peripheral disease and that reovirus in combination with Fludarabine may be useful in targeting drug-resistant lymph node disease.
2015-05-19	Oncolytics Biotech	Regulatory Oncolytics Biotech® Inc. Announces Phase 1 Study in Pediatric Patients with Brain Tumors oncolyticsbiotech.com ↗ is now active.
2015-05-06	Oncolytics Biotech	Regulatory Oncolytics Biotech® Inc. Announces Receipt of Orphan Drug Designation from the U.S. FDA for Gastric Cancer oncolyticsbiotech.com ↗ Oncolytics Biotech Inc. (“Oncolytics”) (TSX:ONC, NASDAQ:ONCY), a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted an Orphan Drug Designation (ODD) for its lead product candidate, REOLYSIN ® , for the treatment of gastric cancers.
2015-04-29	Oncolytics Biotech	Regulatory Oncolytics Biotech® Inc. Announces Receipt of Orphan Drug Status from the EMA for Pancreatic Cancer oncolyticsbiotech.com ↗ the European Medicines Agency (“EMA”) has granted Orphan Drug Designation for its lead product candidate, REOLYSIN ® , for the treatment of pancreatic cancer.
2015-04-17	Oncolytics Biotech	Regulatory Oncolytics Biotech® Inc. Announces Receipt of Orphan Drug Designation from the U.S. FDA for Malignant Gliomas oncolyticsbiotech.com ↗ today announced that the U.S. Food and Drug Administration (FDA) has granted an Orphan Drug Designation (ODD) for its lead product candidate, REOLYSIN ® , for the treatment of malignant glioma.
2015-04-15	Oncolytics Biotech	Results Oncolytics Biotech® Inc. Presents at UK Immuno-oncology Meeting oncolyticsbiotech.com ↗ Updated results from the REO 017 study, in which pancreatic cancer patients received combination therapy with REOLYSIN ® and gemcitabine demonstrated a median overall survival (OS) of 10.2 months, and one- and two-year survival rates of 45% and 24%, respectively.
2015-04-07	Oncolytics Biotech	Regulatory Oncolytics Biotech® Inc. Announces Filing for Orphan Drug Designation with the U.S. FDA for Gastric Cancer oncolyticsbiotech.com ↗ Oncolytics Biotech ® Inc. (“Oncolytics”) (TSX:ONC, NASDAQ:ONCY) today announced that it has submitted an application for Orphan Drug Designation to the U.S. Food and Drug Administration (“FDA”) for REOLYSIN ® for the treatment of gastric cancer.
2015-03-26	Oncolytics Biotech	Results Oncolytics Biotech® Inc. Presents at the 2015 Immune Checkpoint Inhibitors Meeting oncolyticsbiotech.com ↗ REOLYSIN ® inducing the up-regulation of PD-1 and PD-L1 in target tissues in patients with primary glioblastomas or brain metastases, and that this up-regulation is strongly associated with productive reoviral infection (REO 013b)
2015-03-25	Oncolytics Biotech	Regulatory Oncolytics Biotech® Inc. Announces Receipt of Orphan Drug Status from the EMA for Ovarian Cancer oncolyticsbiotech.com ↗ Oncolytics Biotech ® Inc. (“Oncolytics”) (TSX:ONC, NASDAQ:ONCY), a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the European Medicines Agency (“EMA”) has granted Orphan Drug Designation for its lead product candidate, REOLYSIN ® , for the treatment of ovarian, fallopian tube and primary peritoneal cancers.
2015-03-05	Oncolytics Biotech	Results Oncolytics Biotech® Inc. Collaborators Present Preclinical Data on the Combination of REOLYSIN® and Radiotherapy in Melanoma at the Irish Association for Cancer Research Conference oncolyticsbiotech.com ↗ They concluded that the combination of REOLYSIN ® and radiation therapy enhances cytotoxicity in those cell lines by increasing programmed cancer cell death, and that radiation therapy supports increased reovirus replication and suppresses the host cell’s anti-viral defenses.
2015-03-03	Oncolytics Biotech	Regulatory Oncolytics Biotech® Inc. Announces Receipt of Orphan Drug Designation from the U.S. FDA for Primary Peritoneal Cancer oncolyticsbiotech.com ↗
2015-03-02	Oncolytics Biotech	Regulatory Oncolytics Biotech® Inc. Announces Receipt of Orphan Drug Designation from the U.S. FDA for Cancer of the Fallopian Tube oncolyticsbiotech.com ↗ today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its lead product candidate, REOLYSIN ® , for the treatment of cancer of the fallopian tube.
2015-02-17	Oncolytics Biotech	Regulatory Oncolytics Biotech® Inc. Announces Receipt of Orphan Drug Designation from the U.S. FDA for Pancreatic Cancer oncolyticsbiotech.com ↗
2015-02-11	Oncolytics Biotech	Regulatory Oncolytics Biotech® Inc. Announces Receipt of Orphan Drug Designation from the U.S. FDA for Ovarian Cancer oncolyticsbiotech.com ↗ today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its lead product candidate, REOLYSIN ® , for the treatment of ovarian cancer.
2015-02-09	Oncolytics Biotech	Regulatory Oncolytics Biotech® Inc. Announces Filing for Orphan Drug Designation with the U.S. FDA for High Grade Gliomas in Pediatric Patients oncolyticsbiotech.com ↗ Oncolytics Biotech Inc. (“Oncolytics”) (TSX:ONC, NASDAQ:ONCY) today announced that it has submitted an application for Orphan Drug Designation to the U.S. Food and Drug Administration (“FDA”) for REOLYSIN ® for the treatment of high grade gliomas (HGG) in pediatric patients.
2014-12-22	Oncolytics Biotech	Regulatory Oncolytics Biotech® Inc. Announces Filing for Orphan Designation with the EMA for Pancreatic and Ovarian Cancers oncolyticsbiotech.com ↗ Oncolytics Biotech Inc. (“Oncolytics”) (TSX:ONC, NASDAQ:ONCY) today announced that it has submitted applications for Orphan Designation to the European Medicines Agency (“EMA”) for REOLYSIN ® for the treatment of pancreatic and ovarian cancers.
2014-12-04	Oncolytics Biotech	Results Oncolytics Biotech® Inc. Collaborators Present REOLYSIN® and Checkpoint Inhibitor Combination Preclinical Data at AACR Tumor Immunology and Immunotherapy Conference oncolyticsbiotech.com ↗ “The preclinical data presented by our collaborators demonstrates that REOLYSIN ® increases the therapeutic activity of check point inhibitors,” said Dr. Brad Thompson, President and CEO of Oncolytics.
2014-12-02	Oncolytics Biotech	Regulatory Oncolytics Biotech® Inc. Announces Filing for Orphan Drug Designation with the U.S. FDA for Pancreatic and Ovarian Cancers oncolyticsbiotech.com ↗ Oncolytics Biotech Inc. (“Oncolytics”) (TSX:ONC, NASDAQ:ONCY) today announced that it has submitted applications for Orphan Drug Designation to the U.S. Food and Drug Administration (“FDA”) for REOLYSIN ® for the treatment of pancreatic and ovarian cancers.
2014-09-16	Oncolytics Biotech	Results Oncolytics Biotech® Inc. Announces Overall and KRAS-Mutated Patient Data from U.S. Randomized Phase 2 Pancreatic Cancer Study oncolyticsbiotech.com ↗ The median progression free survival for the control arm was 5.16 months (95% confidence interval (CI) = 2.267 to 6.176) versus 5.26 months for the test arm (95% CI = 3.187 to 6.307) (see Figure 1).
2014-05-20	Oncolytics Biotech	Results Oncolytics Biotech® Inc. Collaborators to Present Positive Brain Cancer Clinical Trial Data at the 50th Annual ASCO Meeting oncolyticsbiotech.com ↗ Oncolytics Biotech Inc. (“Oncolytics”) (TSX:ONC) (NASDAQ:ONCY) today announced that an abstract detailing early results from translational study looking at the intravenous administration of REOLYSIN ® to patients with primary or metastatic brain tumors is now available on the ASCO Annual Meeting abstract website at http://abstracts.asco.org .
2014-04-14	Oncolytics Biotech	Results Oncolytics Biotech Inc. Collaborators Present Preclinical Research on Liver Cancer at UK Oncolytic Virus Conference oncolyticsbiotech.com ↗ reovirus inhibits HCC xenograft growth and HCV replication in vivo
2014-04-14	Oncolytics Biotech	Results Oncolytics Biotech Inc. Collaborators Present Head and Neck Cancer Biomarker Preclinical Research at UK Oncolytic Virus Conference oncolyticsbiotech.com ↗ The study results showed that high YAP-1 protein expression correlated with reovirus resistance, whereas low YAP-1 expression correlated with sensitivity to reovirus infection.
2014-04-11	Oncolytics Biotech	Results Oncolytics Biotech Inc. Collaborators Present Translational Brain Cancer Clinical Data and Immunomodulatory Preclinical Research at UK Oncolytic Virus Conference oncolyticsbiotech.com ↗ We have now shown that intravenous reovirus can access tumours in the brain as well as the liver in patients, and combining the virus with granulocyte macrophage colony stimulating factor enhances therapy in a range of pre-clinical cancer models.
2014-04-08	Oncolytics Biotech	Results Oncolytics Biotech® Inc. Announces Additional Data from REO 018 Randomized Study of REOLYSIN® in Head and Neck Cancers oncolyticsbiotech.com ↗ As previously disclosed, under these study conditions, test arm patients in this group had a progression-free survival (PFS) benefit over control arm patients through five cycles of therapy;
2014-04-07	Oncolytics Biotech	Results Oncolytics Biotech Inc. Collaborators to Present Preclinical Research in Multiple Myeloma and Melanoma at AACR 2014 Annual Meeting oncolyticsbiotech.com ↗ The poster presents findings demonstrating that reovirus acts synergistically with carfilzomib and/or perifosine in oncolysis of therapy resistant multiple myeloma cell lines.
2013-11-21	Oncolytics Biotech	Results Oncolytics Biotech® Inc. Announces Positive Top-Line Data from REO 018 Randomized Study of REOLYSIN® in Head and Neck Cancers oncolyticsbiotech.com ↗ The analysis showed a median progression free survival (PFS) of 94 days (13.4 weeks) in the test arm (n=62), versus 50 days (7.1 weeks) in the control arm (n=56).
2013-10-28	Oncolytics Biotech	Results Oncolytics Biotech® Inc. Collaborators Present Positive Data Correlating Specific Biomarkers with Survival in NSCLC Patients Treated with REOLYSIN®, Carboplatin and Paclitaxel oncolyticsbiotech.com ↗ The poster presentation included new efficacy data that correlated a number of molecular abnormalities with best response, progression free survival (PFS) and one-year survival.
2013-10-22	Oncolytics Biotech	Results Oncolytics Biotech® Inc. Announces Progression Free Survival Data for Phase 2 Study of REOLYSIN® in Squamous Cell Lung Cancer oncolyticsbiotech.com ↗ Of the evaluable patients who had more than one cycle of therapy, 23 (92%) exhibited overall tumour shrinkage.
2013-10-01	Oncolytics Biotech	Results Oncolytics Biotech Inc. Collaborators to Present Positive Clinical Trial Data at the 15th Annual World Conference on Lung Cancer oncolyticsbiotech.com ↗ Response evaluation for 36 evaluable patients showed 11 partial responses (PR) (30%) (EGFR amplified, five; BRAF two; Kras , three; EGFR mutated, one), 21 stable disease (SD), and four progressive disease (PD).
2013-09-09	Oncolytics Biotech	Results Oncolytics Biotech® Inc. Announces Positive Final Tumour Response Data for U.S. Phase 2 Study of REOLYSIN® in Squamous Cell Lung Cancer oncolyticsbiotech.com ↗ Of 25 evaluable patients who had more than one cycle of therapy, 23 (92%) exhibited overall tumour shrinkage (mean shrinkage was 32.7%).
2013-05-22	Oncolytics Biotech	Results Oncolytics Biotech® Inc. Meets Primary Endpoint for First Stage of U.S. Phase 2 Metastatic Melanoma Trial oncolyticsbiotech.com ↗ Three of 14 patients exhibited a PR, and an additional seven patients had SD for a disease control rate of 71.5%.
2013-03-28	Oncolytics Biotech	Results Oncolytics Biotech® Inc. Meets Primary Overall Statistical Endpoint in U.S. Phase 2 Study of REOLYSIN® in Squamous Cell Lung Cancer oncolyticsbiotech.com ↗ “We are pleased to have met the response rate endpoint, which builds on the data we announced from the first stage of this study,” said Dr. Brad Thompson , President and CEO of Oncolytics.
2013-02-08	Oncolytics Biotech	Results Oncolytics Biotech® Inc. Announces Additional Positive REOLSYIN® Clinical Trial Data from Phase 2 Study in Squamous Cell Carcinoma of the Lung oncolyticsbiotech.com ↗ Of 20 evaluable patients, 19 (95%) exhibited overall tumour shrinkage, (mean (20 patients): 33.7% shrinkage).
2013-01-28	Oncolytics Biotech	Results Oncolytics Biotech® Inc. Announces Positive REOLSYIN® Clinical Trial Data Presented at ASCO Gastrointestinal Cancers Symposium oncolyticsbiotech.com ↗ Of the 18 patients evaluable for response there was one partial response and nine had stable disease.
2012-12-13	Oncolytics Biotech	Results Oncolytics Biotech Inc. Announces Positive Top Line REOLYSIN® Data for First Endpoint in Randomized Phase III Study in Head and Neck Cancers oncolyticsbiotech.com ↗ Of the 105 total patients with evaluable metastatic tumours, 86 percent (n=50) of those in the test arm of the study exhibited tumour stabilization or shrinkage, compared with 67 percent of patients (n=55) in the control arm.
2012-09-13	Oncolytics Biotech	Results Oncolytics Biotech® Inc. Meets Primary Endpoint for First Stage of U.S. Phase 2 Squamous Cell Lung Cancer Clinical Trial oncolyticsbiotech.com ↗ Five of 15 patients showed PR, four confirmed, one unconfirmed, and an additional eight patients had stable disease (SD), for a disease control rate (complete response (CR) + PR + SD)) of 87%.
2012-09-12	Oncolytics Biotech	Results Oncolytics Biotech Inc. Provides Update on Phase III Study of REOLYSIN® in Head and Neck Cancers oncolyticsbiotech.com ↗ There was a statistically significant difference in PFS between these two groups (n=80, p=0.008, hazard ratio=0.536).
2012-06-20	Oncolytics Biotech	Results Oncolytics Announces Independent Data Monitoring Committee Recommends Continued Enrollment in Phase III Study of REOLYSIN® in Head and Neck Cancers Following Review of Safety Data oncolyticsbiotech.com ↗ Based on the review of the safety data the DMC has recommended that enrollment continue in the study.
2012-06-13	Oncolytics Biotech	Results Oncolytics Biotech® Inc. Announces Publication of Translational Clinical Trial Results in Science Translational Medicine oncolyticsbiotech.com ↗ The researchers demonstrated that even though all the treated patients had preexisting immunity to the virus, intravenously administered reovirus could still specifically target and infect metastatic liver tumors in 90% of the patients.
2012-03-29	Oncolytics Biotech	Results Oncolytics Biotech® Inc. Announces Reovirus Research to be Presented at AACR Annual Meeting oncolyticsbiotech.com ↗ The results show that MPNST-derived cell lines including sporadic MPNST without active Ras were efficiently transduced, promoted virus replication and were killed by the oncolytic reovirus.
2011-12-02	Oncolytics Biotech	Results Oncolytics Biotech® Inc. Announces Phase 2 Clinical Trial of REOLYSIN® in Combination with Gemcitabine in Pancreatic Cancer Reaches Primary Endpoint oncolyticsbiotech.com ↗ To date, eight patients of 13 evaluable patients in the study had stable disease (SD) for 12 weeks or longer, for a clinical benefit rate (complete response (CR) + partial response (PR) + SD) of 62%.
2011-08-02	Oncolytics Biotech	Results Oncolytics Biotech® Inc. Announces Publication of Preclinical Research on Synergistic Combination of Chemotherapy with Oncolytic Virotherapy oncolyticsbiotech.com ↗ The researchers demonstrated that this drug combination was superior to either treatment alone, and were able to reproducibly cure nearly half of the treated animals by employing this optimized schedule of paclitaxel/REOLYSIN.
2011-07-06	Oncolytics Biotech	Results Oncolytics Biotech® Inc. Collaborators Present Positive REOLYSIN® Clinical Trial Results at the 14th World Conference on Lung Cancer oncolyticsbiotech.com ↗ Response evaluation to date in 21 patients showed six partial responses (PR) (28.6%), 13 stable disease (SD) (61.9%), two progressive disease (PD) (9.5%).
2011-06-08	Oncolytics Biotech	Results Oncolytics Biotech® Inc. Collaborators to Present Reovirus Research at the 14th World Conference on Lung Cancer oncolyticsbiotech.com ↗ Grade 3-4 adverse events included grade 4 neutropenia (four patients), anemia, fatigue, electrolyte abnormalities, diarrhea, (two patients), and single cases of nausea, vomiting, and sepsis.
2011-04-20	Oncolytics Biotech	Results Oncolytics Biotech® Inc. Announces Positive Data from Translational Clinical Trial Investigating REOLYSIN® in Patients with Metastatic Colorectal Cancer oncolyticsbiotech.com ↗ On initial histological analysis of the 10 treated patients to date, there was evidence of selective delivery of virus to tumour versus normal liver and viral replication in the majority (seven) of patients.
2011-02-14	Oncolytics Biotech	Results Oncolytics Biotech® Inc. Meets Primary Endpoint for First Part of U.S. Phase 2 Pancreatic Cancer Clinical Trial oncolyticsbiotech.com ↗ This endpoint was met after six evaluable patients were enrolled.
2010-11-29	Oncolytics Biotech	Results Oncolytics Biotech® Inc. Announces Publication of Phase I Clinical Trial Results Examining Combination of REOLYSIN® and Docetaxel in Clinical Cancer Research oncolyticsbiotech.com ↗ Antitumour activity was seen with one complete response (in the liver of a breast cancer patient with no evidence of disease recurrence at the end of the study, following eight cycles of treatment) and three partial responses.
2010-11-01	Oncolytics Biotech	Results Oncolytics Biotech(R) Inc. Collaborators to Present Reovirus Research at the EORTC-NCI-AACR Meeting oncolyticsbiotech.com ↗ The abstract, entitled “REOLYSIN ® induces endoplasmic reticular stress in multiple myeloma and enhances the activity of bortezomib”, authored by Kelly et al , indicates that the REOLYSIN and bortezomib combination significantly reduced tumor burden in both xenograft and syngeneic multiple myeloma mouse models.
2010-10-26	Oncolytics Biotech	Results Oncolytics Biotech® Inc. Collaborators Present Data from U.K. Translational Colorectal Cancer Study at the International Symposium on CTL and Immunostimulation oncolyticsbiotech.com ↗ On histological analysis of six patients to date, there was evidence of replication and tumour cell death in the tumours of four of six patients, two of which had confirmed Kras mutations in codon 12 (the most common ras mutation).
2010-07-19	Oncolytics Biotech	Regulatory Oncolytics Biotech(R) Inc. Receives No Objection Letter from Health Canada to Conduct Phase 3 Trial of REOLYSIN(R) in Head and Neck Cancers oncolyticsbiotech.com ↗
2010-06-07	Oncolytics Biotech	Results Oncolytics Biotech(R) Inc. Collaborators Present Positive Updated U.K. Phase I/II Trial Results in Advanced Solid Cancers with a Focus on the Head and Neck at the ASCO Annual Meeting oncolyticsbiotech.com ↗ The poster entitled “Phase I/II Study of Oncolytic Reovirus Plus Carboplatin/Paclitaxel in Patients with Advanced Solid Cancers with Emphasis on Squamous Cell Carcinoma of the Head and Neck,” (SCCHN) covers previously disclosed response data but includes new overall survival data.
2010-06-01	Oncolytics Biotech	Regulatory Oncolytics Biotech(R) Inc. Receives Approval from Belgium FAMHP to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers oncolyticsbiotech.com ↗
2010-05-21	Oncolytics Biotech	Results Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at ASCO Annual Meeting oncolyticsbiotech.com ↗ PR was seen in eight patients (42%) and stable disease (SD) in six (32%).
2010-05-18	Oncolytics Biotech	Results Oncolytics Biotech(R) Inc. Announces Publication of Phase I Clinical Trial Results in Clinical Cancer Research oncolyticsbiotech.com ↗ The paper covers final results from a Phase Ia/Ib U.K. clinical trial (REO 006) investigating the intratumoural delivery of REOLYSIN(R) in combination with radiation to treat patients with advanced cancers.
2010-04-14	Oncolytics Biotech	Results Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at AACR Annual Meeting oncolyticsbiotech.com ↗ The results provide evidence of viral targeting and replication in peritoneal and ovarian cancer cells after intravenous administration of reovirus to patients.
2010-04-08	Oncolytics Biotech	Results Oncolytics Biotech(R) Inc. Announces Publication of Preclinical Research on Combination of Antiangiogenic Cancer Therapy with Oncolytic Virotherapy oncolyticsbiotech.com ↗ The research demonstrated that combining VEGF(165) inhibitors such as Avastin or Sunitinib with systemic delivery of REOLYSIN(R) leads to substantial regression and cure of established tumors in immunocompetent mice.
2010-02-16	Oncolytics Biotech	Regulatory Oncolytics Biotech(R) Inc. Receives Approval from the U.K. MHRA to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers oncolyticsbiotech.com ↗
2009-11-17	Oncolytics Biotech	Results Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase I/II Trial Results in Advanced Solid Cancers with a Focus on the Head and Neck at the AACR-NCI-EORTC Meeting oncolyticsbiotech.com ↗ Of 19 evaluable patients with head and neck cancer, mostly SCCHN refractory to prior platinum-based chemotherapy for recurrent/metastatic disease, eight experienced partial responses and six had stable disease.
2009-11-06	Oncolytics Biotech	Results Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting oncolyticsbiotech.com ↗ The trial exceeded its established objective with six patients experiencing stable disease for more than six months.
2009-10-02	Oncolytics Biotech	Regulatory Oncolytics Biotech(R) Inc. Reaches Special Protocol Assessment Agreement with the FDA on Design of Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers oncolyticsbiotech.com ↗ Oncolytics Biotech Inc. (“Oncolytics”) (TSX:ONC, NASDAQ:ONCY) today announced that it has reached an agreement with the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process for the design of a Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers.
2009-09-24	Oncolytics Biotech	Results Oncolytics Biotech(R) Inc. Announces Reovirus and Cisplatin Research Supports U.S. Phase 2 Metastatic Melanoma Trial oncolyticsbiotech.com ↗ The research demonstrated that the innate cancer killing activity of reovirus can be enhanced with a variety of commonly available therapeutic agents in models of malignant melanoma.
2009-07-16	Oncolytics Biotech	Results Oncolytics Biotech(R) Inc. Announces Publication of Research on Synergistic Activity of Reovirus and Chemotherapy in NSCLC oncolyticsbiotech.com ↗ When reovirus was used alone, it demonstrated significant cytolytic activity in 7 of 9 NSCLC cell lines examined.
2009-07-15	Oncolytics Biotech	Results Oncolytics Biotech(R) Inc. Research Collaborators Present Glioma Reovirus Research at ASV Annual Meeting oncolyticsbiotech.com ↗ The combination index analyses revealed moderate to strong synergy in primary patient glioma cells treated with reovirus plus IR and TMZ in vitro.
2009-06-01	Oncolytics Biotech	Results Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting oncolyticsbiotech.com ↗ One patient had SD for more than 80 weeks.
2008-12-11	Oncolytics Biotech	Results Oncolytics Biotech Inc.’s REOLYSIN(R) Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study oncolyticsbiotech.com ↗ Oncolytics Biotech Inc. (“Oncolytics”) (TSX:ONC, NASDAQ:ONCY) announced today that it has exceeded the primary statistical endpoint in its multi-centre Phase 2 clinical trial to evaluate the intravenous administration of REOLYSIN(R) in patients with various sarcomas that have metastasized to the lung.
2008-11-14	Oncolytics Biotech	Results Oncolytics Biotech Inc. Collaborators to Present REOLYSIN(R) Research at CTOS Annual Meeting oncolyticsbiotech.com ↗ The researchers concluded that in all tumour lines evaluated, REOLYSIN(R) exhibits significant antitumour activity, including a complete response in a rhabdomyosarcoma line.
2008-11-06	Oncolytics Biotech	Results Oncolytics Biotech Inc. Investigators Present Interim U.S. REOLYSIN(R) Phase II Sarcoma Trial Data oncolyticsbiotech.com ↗ 21% (6/29) of the evaluable patients experienced stable disease (SD) for more than 16 weeks.
2008-11-03	Oncolytics Biotech	Results Oncolytics Biotech Inc. Collaborators Present Positive Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Results at iSBTc Annual Meeting oncolyticsbiotech.com ↗
2008-11-03	Oncolytics Biotech	Results Oncolytics Biotech Inc. Collaborators Present Positive Combination REOLYSIN(R) and Docetaxel Results at iSBTc Annual Meeting oncolyticsbiotech.com ↗ Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that it has achieved positive interim results in its U.K. combination REOLYSIN(R) and docetaxel clinical trial for patients with advanced cancers.
2008-10-23	Oncolytics Biotech	Results Oncolytics Biotech Inc. Collaborators to Present Combination REOLYSIN(R) and Paclitaxel/Carboplatin Results at iSBTc Annual Meeting oncolyticsbiotech.com ↗ Of the 10 evaluable patients, there were three patients with a partial response, five patients with stable disease and two patients with progressive disease.
2008-10-23	Oncolytics Biotech	Results Oncolytics Biotech Inc. Collaborators to Present Combination REOLYSIN(R) and Docetaxel Results at iSBTc Annual Meeting oncolyticsbiotech.com ↗ The researchers concluded that REOLYSIN(R) can be safely combined with docetaxel, that there was objective radiological evidence of anticancer activity and that Phase II studies with this combination are justified.
2008-10-22	Oncolytics Biotech	Results Oncolytics Biotech Inc. Collaborators to Present Preclinical Combination REOLYSIN(R) and Cisplatin Research at EORTC-NCI-AACR Annual Meeting oncolyticsbiotech.com ↗ The researchers demonstrated that the combined therapy results in significantly increased cell death in vitro compared to either agent alone.
2008-06-02	Oncolytics Biotech	Results Oncolytics Biotech Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting oncolyticsbiotech.com ↗ The interim results demonstrate that the treatment has been well tolerated to date, with 8 of 16 evaluable patients experiencing stable disease for periods ranging from two to more than ten, 28-day cycles.
2008-05-30	Oncolytics Biotech	Results Oncolytics Biotech Inc. Collaborators to Present Reovirus Research at ASGT Meeting oncolyticsbiotech.com ↗ In this study, the investigators demonstrated that normal T-cells pre-loaded with reovirus localize to lymph nodes, spleen and liver and deliver the virus to sites of metastatic disease.
2008-05-14	Oncolytics Biotech	Regulatory Oncolytics Biotech Inc. Announces U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin oncolyticsbiotech.com ↗ it has received a letter of approval from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) for its Clinical Trial Application (CTA) to begin a Phase II clinical trial
2008-03-17	Oncolytics Biotech	Results Oncolytics Biotech Inc. Announces Publication of Research on Immune Response to REOLYSIN(R) during a Phase I Clinical Trial oncolyticsbiotech.com ↗ The results suggest that reovirus may stimulate the immune system to mount a dynamic immune response to the presence of virus, increasing the potential to significantly enhance the efficacy of oncolytic virotherapy.
2008-03-13	Oncolytics Biotech	Results Oncolytics Biotech Inc. Collaborators to Present Reovirus Research at AACR Annual Meeting oncolyticsbiotech.com ↗ The results demonstrated that the combination of reovirus and radiation significantly enhanced efficacy compared to either treatment alone in terms of tumour regression and event free survival.
2008-02-04	Oncolytics Biotech	Results Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Radiation Therapy oncolyticsbiotech.com ↗ The results demonstrated that combining reovirus and radiotherapy significantly increased cancer cell killing both in vitro and in vivo, particularly in cell lines with moderate susceptibility to reovirus alone.
2008-01-31	Oncolytics Biotech	Results Oncolytics Biotech Inc. Proceeds to Full Enrolment in U.S. Phase II Sarcoma Clinical Trial oncolyticsbiotech.com ↗ The third patient treated in the study was demonstrated to have stable disease by RECIST criteria for more than six months as measured by CT scan.
2008-01-07	Oncolytics Biotech	Results Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Cyclophosphamide Treatment oncolyticsbiotech.com ↗ The data support investigation in human clinical trials of the use of cyclophosphamide prior to systemic reovirus administration to modulate, but not ablate, the immune system.
2008-01-03	Oncolytics Biotech	Regulatory Oncolytics Biotech Inc. Announces Filing of Phase 1/2 Clinical Trial with REOLYSIN(R) oncolyticsbiotech.com ↗
2007-10-24	Oncolytics Biotech	Results Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial oncolyticsbiotech.com ↗ The interim results of the Ia/Ib trial demonstrate that intratumoural treatment with REOLYSIN(R) and radiation is well tolerated and results in both local and remote anti-tumour activity in patients with a variety of advanced cancers.
2007-10-23	Oncolytics Biotech	Regulatory Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide oncolyticsbiotech.com ↗
2007-09-28	Oncolytics Biotech	Results Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial oncolyticsbiotech.com ↗ Of these 11 patients, three patients (oesophageal, squamous skin carcinoma and squamous cell scalp) experienced significant partial responses.
2007-06-05	Oncolytics Biotech	Results Oncolytics Biotech Inc. Announces Positive Clinical Data from U.S. Phase I REOLYSIN(R) Trial oncolyticsbiotech.com ↗ Oncolytics Biotech Inc. (“Oncolytics”) (TSX:ONC, NASDAQ:ONCY) announced today positive results from its U.S. Phase I clinical trial examining the systemic administration of REOLYSIN(R) in patients with advanced cancers.
2007-05-14	Oncolytics Biotech	Regulatory U.S. NCI Files for Phase 2 Systemic Melanoma Clinical Trial with REOLYSIN(R) oncolyticsbiotech.com ↗
2007-04-17	Oncolytics Biotech	Results Oncolytics Biotech Inc. Research Collaborators Demonstrate Reovirus/Gemcitabine Combination Has Synergistic Effect Against Human Colon Cancer Cell Lines oncolyticsbiotech.com ↗ The researchers found that treatment of human colon cancer cell lines with the combination of REOLYSIN(R) and gemcitabine resulted in both in vitro and in vivo synergy.
2007-03-16	Oncolytics Biotech	Results Oncolytics Biotech Inc. Research Collaborators to Present Reovirus Treatment in Melanoma Animal Models at International Oncolytic Virus Conference oncolyticsbiotech.com ↗ The results of the preclinical study showed that the reovirus effectively replicated in and killed a range of human melanomas in vitro, and intratumoural injection of reovirus significantly delayed tumour growth in a mouse implanted with a human melanoma tumour.
2007-01-10	Oncolytics Biotech	Results Oncolytics Biotech Inc. Research Collaborators to Present Reovirus Data at Society of Academic & Research Surgery Conference oncolyticsbiotech.com ↗ The results showed that a significant proportion of tumour cell cultures showed susceptibility to death following reovirus infection, and also demonstrated effective replication of reovirus within these cells.
2007-01-03	Oncolytics Biotech	Regulatory Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Gemcitabine oncolyticsbiotech.com ↗
2007-01-03	Oncolytics Biotech	Regulatory Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Docetaxel oncolyticsbiotech.com ↗ Oncolytics Biotech Inc. (“Oncolytics”) (TSX:ONC, NASDAQ:ONCY) announced today that it has received a letter of approval from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) for its Clinical Trial Application (CTA) to begin a clinical trial using intravenous administration of REOLYSIN(R) in combination with docetaxel (Taxotere(R)) in patients with advanced cancers including bladder, prostate, lung and upper gastro-intestinal.

All press releases naming this drug 281 releases

Date	Issuer	Release
Show all 281 releases opens the full record — a long page

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 29 sources stand behind the page.

Field	Value	Cited text
Known as	REOLYSIN	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00998322 ↗ 15 NCT00984464 ↗ NCT00503295 ↗ NCT03282188 ↗ NCT01622543 ↗ NCT01274624 ↗ NCT00861627 ↗ NCT00528684 ↗ NCT01619813 ↗ NCT02723838 ↗ NCT00998192 ↗ Show 5 more sources
Known as	Pelareorep	“OBJECTIVES: Pelareorep (reolysin), a Dearing strain of reovirus serotype 3, has demonstrated oncolytic activity as single agent and synergy with chemotherapy.” PMID 29748010 ↗ Mar 2018 12 “Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma.” PMID 27039845 ↗ Apr 2016 “Patients also receive Pelareorep IV over 60 minutes on days 1, 2, 3, and 8 in course 1 and on days 1 and 8 of subsequent courses.” NCT03723915 ↗ NCT04102618 ↗ NCT04445844 ↗ NCT07446322 ↗ NCT07280377 ↗ NCT02101944 ↗ NCT04215146 ↗ NCT03605719 ↗ NCT05519059 ↗ Show 2 more sources
Known as	Previously REOLYSIN	“Previously REOLYSIN®” NCT04102618 ↗
Known as	Reovirus Serotype 3 - Dearing Strain	“Reovirus Serotype 3 - Dearing Strain (REOLYSIN®) is a naturally occurring, ubiquitous, non-enveloped human reovirus.” NCT02723838 ↗
Known as	Reovirus Type 3 Dearing	“A Phase 2 Study of Intravenous Administration of REOLYSIN (Reovirus Type 3 Dearing) in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma” NCT00984464 ↗ 1 “REOLYSIN® (Reovirus Type 3 Dearing)” NCT00998192 ↗
Modality	Other / unclassified	“unmodified oncolytic reovirus” NCT00503295 ↗
Route	Intravenous	“given intravenously” NCT00503295 ↗